EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study

Eunwoo Kim, Wonsuk Shin, Hyounggyoon Yoo, Yilseob Lee, Kwang Hyun Ahn, Anhye Kim

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-07 · 399 (10) · 16199-16207

DOI: 10.1007/s00210-026-05374-x ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 09.05.2026. Verfasst von Eunwoo Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology & Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Republic of Korea. Hauptthemen laut MEDLINE: Alanine, Anti-HIV Agents, Tenofovir. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Jeil Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study compared the pharmacokinetic bioequivalence and safety of a new free-base formulation of 25 mg tenofovir alafenamide (TAF) to those of a reference formulation under fasting conditions. In this phase I, randomized, open-label, two-sequence, four-period, fully replicated crossover trial, 48 healthy volunteers were enrolled to receive single doses of the test and reference formulations in the T-R-T-R or R-T-R-T sequences. The plasma concentrations of TAF and tenofovir were measured and analyzed using non-compartmental methods. As the TAF concentration exhibits high intra-individual variability, reference-scaled average bioequivalence can be applied. The safety and tolerability were monitored during the study. All 48 volunteers received the study drug at least once. The pharmacokinetic analysis included 44 and 46 volunteers for TAF and tenofovir, respectively. The intra-individual coefficient of variation for the plasma maximum concentration (Cmax) of the reference TAF formulation was 59.86%, permitting an expanded acceptance range of 0.6984–1.4319. Both TAF and tenofovir met the bioequivalence criteria as the geometric mean ratios (test/reference) and 90% confidence intervals for the Cmax and AUClast of each substance were within 0.80–1.25. Both formulations were safe and well-tolerated, and no serious adverse events were observed. The novel free-base formulation of 25 mg TAF demonstrated pharmacokinetic bioequivalence with the reference formulation and was safe for use in healthy volunteers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlanineAnti-HIV AgentsTenofovirAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveCross-Over StudiesHealthy VolunteersTherapeutic Equivalency

Stichwörter der Autor:innen

BioequivalencePharmacokineticsPhase 1 clinical trialTenofovir alafenamide

Substanzen

AlanineAnti-HIV AgentsTenofovirtenofovir alafenamide

Autor:innen und Institutionen

  • Department of Clinical Pharmacology & Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Republic of Korea.
  • Department of Physiology, CHA University School of Medicine, Pocheon-Si, Republic of Korea.
  • Department of Pharmacology, CHA University School of Medicine, Pocheon-Si, Republic of Korea.
  • Product Development Division, Jeil Pharmaceutical Co. Ltd., Seoul, Republic of Korea.
  • Department of Clinical Pharmacology & Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Republic of Korea. ahkim3478@gmail.com.
  • Department of Pharmacology, CHA University School of Medicine, Pocheon-Si, Republic of Korea. ahkim3478@gmail.com.

Förderung

  • Jeil Pharmaceutical Co., Ltd.

Zitieren

APA

Kim, E., Shin, W., Yoo, H., Lee, Y., Ahn, K. H., & Kim, A. (2026). Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(10), 16199-16207. https://doi.org/10.1007/s00210-026-05374-x

Vancouver

Kim E, Shin W, Yoo H, Lee Y, Ahn KH, Kim A. Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(10):16199-16207. doi:10.1007/s00210-026-05374-x

BibTeX
@article{Kim2026,
  author = {Kim, Eunwoo and Shin, Wonsuk and Yoo, Hyounggyoon and Lee, Yilseob and Ahn, Kwang Hyun and Kim, Anhye},
  title = {Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  volume = {399},
  number = {10},
  pages = {16199--16207},
  doi = {10.1007/s00210-026-05374-x}
}
Kostenlos starten →